Table 4 Maternal outcomes between the TDF treatment and control groups.
TDF Group Mean ± SD or n (%) | Control Group Mean ± SD or n (%) | p | |
|---|---|---|---|
Mothers | |||
Pregnancy weeks | 39.46 ± 1.43 | 39.33 ± 1.49 | 0.645 |
Cesarean section, n (%) | 21 (36.2%) | 17 (32.7%) | 0.699 |
Obstetric complications, n (%) | |||
Pregnancy hypertension | 0 | 0 | |
Placenta previa | 0 | 0 | |
Intrahepatic cholestasis of pregnancy | 6 (10.3%) | 5 (9.6%) | 0.899 |
Postpartum hemorrhage | 0 | 0 | |
Limited fetal growth | 0 | 0 | |
Preterm birth | 1 (1.69%) | 2 (3.85%) | 0.495 |
Abortion | 1 (1.72%) | 0 | 0.342 |
Adverse reactions, n (%) | |||
Digestive tract reaction: vomiting | 2 (3.45%) | 0 | 0.177 |
Fatigue | 0 | 0 | |
Headache | 0 | 0 | |
Cough | 0 | 0 | |
Fever | 0 | 0 | |
Itchy skin | 6 (10.3%) | 5 (9.6%) | 0.899 |
Jaundice | 0 | 0 | |
Laboratory examinations, n (%) | |||
ALT, U/L >5 × ULN* | 2 (3.45%) | 0 | 0.177 |
Renal dysfunction | 0 | 0 | |
Decrease of PLT | 0 | 0 | |
Anemia | 0 | 0 | |
